---
title: "GLP-1 स्पष्ट: भारतीय रुग्णां साठी संपूर्ण मार्गदर्शक"
description: "जाणून घ्या GLP-1 रिसेप्टर एगोनिस्ट कसे काम करते हैं, किसकी मदद करते हैं, आणि भारतीय रुग्णां को पहुँच, सुरक्षा आणि realistic अपेक्षाओं के बारे मध्ये काय जानना चाहिए।"
canonical: "https://www.kesho.health/mr/blog/glp-1-explained-india"
markdown_url: "https://www.kesho.health/md/mr/blog/glp-1-explained-india"
date_published: "Jun 15, 2026"
date_modified: "Jun 26, 2026"
author: "Dr. Ananya Mehta"
language: "mr-IN"
primary_keyword: "GLP-1 explained India"
---

# GLP-1 स्पष्ट: भारतीय रुग्णां साठी संपूर्ण मार्गदर्शक

> **Short answer:** GLP-1 रिसेप्टर एगोनिस्ट (GLP-1 RA) injectable आणि oral औषधओं का वर्ग है जो gut hormone की नकल कर भूक कम, पोट खाली होना धीमा आणि रक्त साखर नियंत्रण मध्ये मदद करता है। भारतात BMI ≥27.5 kg/m² या ≥25 सह-रोगों पर type 2 मधुमेह आणि चुनिंदा मोटापा साठी प्रिस्क्राइब। वैद्य की प्रिस्क्रिप्शन, CDSCO-स्वीकृत स्रोत आणि क्रमिक titration आवश्यक। RSSDI/ICMR दिशानिर्देश भारतीय clinicians के उपयोग को आकार देते हैं। Kesho फक्त शिक्षण—प्रिस्क्राइब/बेचते नाही. खरीद से पहले स्वीकृति verify करें।

**Canonical HTML:** https://www.kesho.health/mr/blog/glp-1-explained-india  
**Markdown:** https://www.kesho.health/md/mr/blog/glp-1-explained-india


*Semaglutide या tirzepatide सुनकर सोचते हैं कि आपसाठी सही है या नाही—आप अकेले नाही. GLP-1 RA ने worldwide type 2 मधुमेह आणि obesity approach बदला—भारत भी अपवाद नाही. यह मार्गदर्शक GLP-1 काय हैं, शरीर मध्ये कसे काम करते हैं, आणि RSSDI, ICMR, CDSCO के तहत भारतीय रुग्णां साठी पहुँच, लागत, सुरक्षा मध्ये काय मायने रखता है। नया T2D, central obesity normal BMI, या परिवार सदस्य—drug class समझना (brand marketing नाही) productive चिकित्सा बातचीत की नींव। दक्षिण एशियाई metabolic patterns, कम insurance, generic access—2026 मध्ये drug-class literacy पहले से अधिक मूल्यवान।*

*Reviewed by Dr. Ananya Mehta, MD, DM Endocrinology. This article has been reviewed by our medical advisory team, including endocrinologists, internal medicine specialists, and cardiologists, and is based on current scientific evidence and Indian clinical guidelines. Last reviewed: June 2026.*

## Key takeaways

- GLP-1 रिसेप्टर एगोनिस्ट एक औषध वर्ग हैं—एक उत्पाद नाही—जो प्राकृतिक gut hormone की नकल कर रक्त साखर सुधारता आणि भूक कम करता है।
- भारतात RSSDI आणि ICMR पहले BMI thresholds (≥27.5 या ≥25 सह-रोगों) समर्थन करते हैं क्योंकि दक्षिण एशियाई कम वज़न पर metabolic रोग विकसित करते हैं।
- सभी GLP-1 RA Schedule H प्रिस्क्रिप्शन औषधे; CDSCO अनस्वीकृत import आणि social-media sellers के खिलाफ चेतावनी।
- dose titration से सप्ताहों मध्ये लाभ; पहले महीने मळमळ आम, छोटे भोजन आणि क्रमिक खुराक बढ़ोतरी से सुधार।
- औषध भारतीय dietary patterns, physical activity, regular monitoring के साथ सर्वश्रेष्ठ—अकेले shortcut नाही.


## At a glance (India)

| Field | Value |
| --- | --- |
| Drug schedule in India | Schedule H (prescription only) |
| Typical monthly cost | ₹8,000–₹25,000 out of pocket |
| Obesity BMI threshold (ICMR) | ≥27.5 kg/m², or ≥25 with comorbidities |
| Time to notice weight change | Often 8–12 weeks with titration |
| South Asian waist risk (men / women) | >90 cm / >80 cm |
| Regulatory authority | CDSCO approval required for all products |


## In this article

- What is GLP-1?
- How GLP-1 RAs work
- Approved uses in India
- The thin-fat phenotype
- Access and prescription rules
- GLP-1 vs older diabetes drugs
- Oral vs injectable options
- What to expect month by month
- GLP-1 regulation in India
- Common myths debunked
- What Kesho does and does not do
- GLP-1 with other diabetes drugs
- Kidney and heart benefits
- Molecules available in India
- Ageing and GLP-1 therapy
- PCOS and metabolic health
- Preparing for your first visit


## GLP-1 काय है?

GLP-1 (glucagon-like peptide-1) भोजन के बाद आतडे से निकलने वाला hormone है। रक्त साखर बढ़ने पर स्वादुपिंड से insulin, glucagon कम, मस्तिष्क को संतोष संकेत। GLP-1 RA इस hormone की नकल। औषध वर्ग—एक brand नाही—semaglutide, liraglutide, dulaglutide, dual GIP/GLP-1 tirzepatide। भारतात Schedule H: registered practitioner की valid prescription। CDSCO approval, labelling, pharmacovigilance। Drug class समझ brand marketing से बच informed बातचीत। कई metformin/lifestyle से HbA1c नियंत्रण न हो या modest BMI पर insulin resistance/fatty liver—तब पहली बार GLP-1 RA। RSSDI first-line अपर्याप्त glycaemic targets पर GLP-1 RA महत्वपूर्ण विकल्प।

### GLP-1 receptor agonist

स्वादुपिंड, मस्तिष्क, gut मध्ये GLP-1 receptors सक्रिय—रक्त साखर नियंत्रण आणि भूक कम।

## GLP-1 RA शरीर मध्ये कसे काम करते हैं?

GLP-1 RA लेने पर क्रम में: glucose elevated हो तभी insulin—sulfonylurea की तुलना मध्ये low blood sugar कम जोखिम; gastric emptying धीमा, छोटे हिस्से मध्ये संतोष; brain appetite centres—cravings/emotional eating कम। STEP (semaglutide), SURMOUNT (tirzepatide) lifestyle के साथ meaningful weight/HbA1c। dose titration से सप्ताहों मध्ये प्रभाव—पहले 2-3 महीने धैर्य। शुरुई weeks मळमळ, body adapt/doses slow increase—dose titration doctor guide। भारतीय बड़े traditional meals: delayed emptying unfamiliar; छोटे frequent portions heavy dinner से बेहतर।

## भारतात GLP-1 के approved uses?

भारतात GLP-1 RA मुख्यतः T2D adults—diet, exercise, metformin अपर्याप्त। RSSDI better glycaemic control, CVD risk, obesity, CKD, hypoglycaemia concerns। Obesity: ICMR/RSSDI Western से lower BMI—South Asian lower weights पर metabolic complications। BMI 27.5+ या 25+ prediabetes, fatty liver, hypertension, dyslipidaemia pharmacotherapy। Final eligibility physician full history/medicines/investigations। CVD outcome trials glucose से beyond benefits। T1D/indicated नाही; DKA मध्ये insulin substitute नाही.

Kesho GLP-1 prescribe/sell नाही. शैक्षिक लेख। personalised advice: qualified endocrinologist, internal medicine specialist, cardiologist।

## भारतीय BMI thresholds Western से क्यों अलग?

भारतीय/दक्षिण एशियाई "thin-fat" phenotype: scale पर normal/modest BMI, अधिक visceral fat, कम muscle। insulin resistance, fatty liver, early T2D। Mumbai BMI 26 Europe BMI 26 से अधिक metabolic risk। RSSDI/ICMR earlier intervention। "Normal" weight central obesity, elevated HbA1c, fatty liver ultrasound—GLP-1 broader metabolic plan। Waist >90 cm men, >80 cm women South Asia। Body composition scale number से अधिक—Western online calculators Indian patients misleading।

## भारतात GLP-1 legally कसे access?

Innovator आणि CDSCO-approved generic semaglutide patent developments के बाद। मासिक ₹8,000–₹25,000—अणु, dose, city। Licensed pharmacy, valid prescription। CDSCO unapproved imports, compounded, social-media steep discounts warnings। CDSCO approval, labelling, batch, expiry verify। Injectable pens 2–8°C refrigeration first use; after use <30°C weeks CDSCO guidelines। Metro pharmacists cold-chain familiar; tier-2/3 dispensing counter storage confirm।

### GLP-1 RA common diabetes medicines से तुलना?

- विशेषता: Primary action — GLP-1 RA: GLP-1 hormone mimic; appetite कम — Metformin: liver glucose output कम — Sulfonylureas: insulin release
- विशेषता: Weight effect — GLP-1 RA: Usually loss — Metformin: Neutral/slight loss — Sulfonylureas: Often gain
- विशेषता: Hypoglycaemia risk alone — GLP-1 RA: Low — Metformin: Very low — Sulfonylureas: Moderate to high
- विशेषता: Route India — GLP-1 RA: Injection (weekly/daily) or oral — Metformin: Oral — Sulfonylureas: Oral
- विशेषता: Typical RSSDI position — GLP-1 RA: After metformin if unmet — Metformin: First-line T2D — Sulfonylureas: Declining hypoglycaemia/weight

## Frequently asked questions

### Is GLP-1 the same as insulin?

No. GLP-1 receptor agonists stimulate your pancreas to release insulin when blood sugar is high, but they are not insulin injections. They also reduce appetite and slow digestion—effects insulin does not provide. Some patients use both, but only under medical supervision.

### Can I buy GLP-1 injections without a prescription in India?

No. GLP-1 RAs are Schedule H prescription-only medicines in India. Purchasing from unlicensed online sellers or without a prescription is illegal and unsafe. CDSCO has warned against counterfeit and unapproved imports.

### How long before I see results?

Blood sugar improvements may appear within 4–8 weeks as doses titrate upward. Weight changes typically become noticeable after 8–12 weeks when therapeutic doses are reached. Maximum benefits often require 3–6 months of consistent use alongside diet and activity changes. Indian patients with lower starting BMI may notice metabolic lab improvements before dramatic scale changes—track HbA1c and waist circumference alongside weight. Patience during titration is essential; rushing doses to speed results usually worsens nausea without accelerating outcomes.

### Are GLP-1 medications safe for all Indians with diabetes?

Not for everyone. They are avoided or used cautiously in pregnancy, certain thyroid conditions (personal or family history of medullary thyroid carcinoma or MEN2), severe pancreatitis history, and some gastrointestinal disorders. Your doctor will screen you before prescribing.

### Do I need to take GLP-1 injections forever?

Duration varies by indication and individual response. Many patients with type 2 diabetes use GLP-1 RAs long term for glycaemic and cardiovascular benefit when RSSDI treatment goals are met. For obesity, some patients taper after reaching goals under medical supervision, but weight regain is common without sustained lifestyle support—discuss a maintenance plan with your doctor before stopping. Cost and side-effect tolerance also influence how long therapy continues in Indian practice.

### What is the difference between semaglutide and tirzepatide?

Semaglutide is a GLP-1 RA. Tirzepatide activates both GIP and GLP-1 receptors (a dual incretin agonist). Both are prescription medicines with different dosing, side-effect profiles, and costs. Your doctor selects based on your clinical profile.

### Can GLP-1 RAs be used with SGLT2 inhibitors?

Yes—specialists often combine GLP-1 RAs with SGLT2 inhibitors when HbA1c remains above target despite metformin and lifestyle. RSSDI supports rational combination therapy based on individual cardiovascular, renal, and glycaemic profiles. Never add medicines without physician review of your full regimen.

### What happens during a missed weekly injection?

If fewer than five days have passed since the missed semaglutide dose, take it when remembered. If more than five days have passed, skip and resume on your regular day. Never double doses. Rules vary slightly by product—follow your CDSCO-approved package insert and doctor's instructions.

### Are GLP-1 RAs suitable for patients with heart disease?

GLP-1 RAs have cardiovascular outcome data in high-risk type 2 diabetes patients with established atherosclerotic disease for some molecules. RSSDI incorporates cardiovascular benefit into treatment selection. Heart failure and specific cardiac conditions require individual specialist assessment—not all patients qualify automatically.

## People also ask

### What is the difference between GLP-1 and insulin?

Insulin directly lowers blood sugar by replacing or supplementing the hormone your pancreas makes. GLP-1 receptor agonists stimulate your own insulin release only when glucose is elevated, slow digestion, and reduce appetite. They are different drug classes with different injection schedules, side effects, and prescribing rules. Some patients use both under specialist supervision.

### Are GLP-1 injections painful?

Most weekly pens use very fine needles designed for subcutaneous injection in the abdomen, thigh, or upper arm. Pain is usually mild—a brief pinch. Rotating injection sites reduces bruising. Pharmacists and diabetes educators in India can demonstrate technique at your first prescription fill.

### Can GLP-1 medications cure type 2 diabetes?

They do not cure diabetes. GLP-1 RAs help control blood sugar, support weight loss, and may reduce cardiovascular risk in selected patients, but stopping medication without lifestyle support often leads to glucose and weight rebound. Think of them as long-term tools in a broader metabolic plan.

### Do I need to refrigerate GLP-1 pens in Indian summers?

Unopened injectable pens should be stored between 2°C and 8°C per CDSCO-approved labelling. After first use, most pens tolerate room temperature below 30°C for several weeks. During heat waves or travel, use a insulated pouch and avoid leaving pens in a parked car.

### Is GLP-1 therapy covered by Indian health insurance?

Coverage is limited. Most standard policies exclude obesity pharmacotherapy. Some corporate plans partially cover GLP-1 RAs for type 2 diabetes with prior authorisation. CGHS and state schemes vary. Budget for out-of-pocket costs unless your insurer confirms coverage in writing.

### Can vegetarians and Jains use GLP-1 receptor agonists?

Yes. GLP-1 RAs are synthetic peptide medications, not animal-derived food products. Dietary preference does not affect safety. Nutritional planning alongside therapy should still meet protein and micronutrient needs within your dietary pattern—RSSDI emphasises medical nutrition therapy for all patients.

### How do GLP-1 RAs fit with Ayurvedic or home remedies?

Disclose all supplements and herbal preparations to your doctor. Some traditional glucose-lowering remedies may compound effects when combined with diabetes medicines, increasing hypoglycaemia risk. GLP-1 RAs should not replace evidence-based care or CDSCO-approved prescribing.

### What happens if I stop GLP-1 therapy suddenly?

Abrupt stopping without medical guidance can reverse appetite control and glycaemic benefits. Weight regain is common within months. If cost, side effects, or personal circumstances require stopping, work with your endocrinologist on a taper and maintenance plan.

### Are compounded or imported GLP-1 products safe in India?

CDSCO has issued advisories against unapproved imports, compounded formulations, and medicines sold through unlicensed online channels. Only purchase CDSCO-approved products from licensed pharmacies with a valid prescription, verifiable batch numbers, and proper cold-chain handling.

### How long do GLP-1 pens last after opening?

Most weekly injectable pens remain stable at room temperature below 30°C for several weeks after first use, per CDSCO-approved labelling—typically four to six weeks depending on product. Unopened pens require refrigeration between 2°C and 8°C. Check your specific package insert and discard expired or improperly stored pens.

### Can GLP-1 therapy help with fatty liver disease?

Weight loss of five to ten percent body weight often reduces hepatic steatosis in NAFLD. GLP-1 RAs support weight and glycaemic goals that benefit fatty liver, but alcohol reduction and dietary quality remain essential. Individual assessment by your hepatologist or endocrinologist is required before starting.

## References

1. [RSSDI Clinical Practice Recommendations for Management of Type 2 Diabetes Mellitus (2023). Research Society for Study of Diabetes in India.](https://rssdi.in/)
2. [ICMR Expert Group. (2024). National Guidelines for Obesity Management in India. Indian Council of Medical Research.](https://www.icmr.gov.in/)
3. [Wilding JPH, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM, 384(11), 989-1002.](https://pubmed.ncbi.nlm.nih.gov/33567185/)
4. [Joshi SR, et al. (2012). The Asian Indian Phenotype: Unique Clinical and Biochemical Characteristics. JAPI, 60(Suppl), 5-8.](https://pubmed.ncbi.nlm.nih.gov/23165626/)
5. [CDSCO. Drug Alerts and Advisories on GLP-1 Receptor Agonists. Central Drugs Standard Control Organisation, Govt. of India.](https://cdsco.gov.in/)


## Related guides

- [semaglutide-india-complete-guide](https://www.kesho.health/blog/semaglutide-india-complete-guide) · [MD](https://www.kesho.health/md/blog/semaglutide-india-complete-guide)
- [who-qualifies-glp-1-india](https://www.kesho.health/blog/who-qualifies-glp-1-india) · [MD](https://www.kesho.health/md/blog/who-qualifies-glp-1-india)
- [glp-1-cost-india-2026](https://www.kesho.health/blog/glp-1-cost-india-2026) · [MD](https://www.kesho.health/md/blog/glp-1-cost-india-2026)
- [how-to-talk-to-doctor-glp-1-india](https://www.kesho.health/blog/how-to-talk-to-doctor-glp-1-india) · [MD](https://www.kesho.health/md/blog/how-to-talk-to-doctor-glp-1-india)


---
*Kesho provides GLP-1 education only. We do not prescribe or sell medications. [Editorial policy](https://www.kesho.health/editorial-policy).*